The tariff classification of Isosulfan Blue Injection 1% in dosage form, from Ireland
Issued October 16, 2015 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 3006.30.5000
Headings: 3006
Product description
The subject product, Isosulfan Blue Injection 1%, is a contrast agent that is indicated for lymphatic vessel delineation and for lymphography. It is supplied in 5 mL single use vials and administered subcutaneously one half (1/2) mL into three (3) interdigital spaces of each extremity per study.
CBP rationale
The applicable subheading for the Isosulfan Blue Injection 1% in dosage form, will be 3006.30.5000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Pharmaceutical goods specified in note 4 to this chapter: Opacifying preparations for X-ray examinations; diagnostic reagents designed to be administered to the patient: Other.
Full text
N269294 October 16, 2015 CLA-2-30:OT:RR:NC:2:238 CATEGORY: Classification TARIFF NO.: 3006.30.5000 Ms. Kelly Jo Cox Mylan Pharmaceuticals Inc. 781 Chestnut Ridge Road Morgantown, WV 26505 RE: The tariff classification of Isosulfan Blue Injection 1% in dosage form, from Ireland Dear Ms. Cox: In your letter dated September 30, 2015, you requested a tariff classification ruling. The subject product, Isosulfan Blue Injection 1%, is a contrast agent that is indicated for lymphatic vessel delineation and for lymphography. It is supplied in 5 mL single use vials and administered subcutaneously one half (1/2) mL into three (3) interdigital spaces of each extremity per study. The applicable subheading for the Isosulfan Blue Injection 1% in dosage form, will be 3006.30.5000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Pharmaceutical goods specified in note 4 to this chapter: Opacifying preparations for X-ray examinations; diagnostic reagents designed to be administered to the patient: Other.” The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected]. Sincerely, Gwenn Klein Kirschner Director National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification and country of origin of Fluorescein Injection, USP in dosage form
The tariff classification and country of origin of Indocyanine Green Injection, USP in dosage form
The tariff classification of Gadobutrol Injection in dosage form, from China
The tariff classification of Gadoterate Meglumine Injection in dosage form, from China
The tariff classification of Chemical Compounds from China
The tariff classification of Chemical Compounds from China
The tariff classification of Magnevist® (Gadopentetate Dimeglumine) injection from Germany
The tariff classification of the TOXIKATOR skin pH tester from Germany
The tariff classification of Indigo Carmine Solution, USP, from Ireland
"Hexabrix"; diagnostic imaging contrast medium; ioxaglic acid; 2924.29.4400; NAFTA; Article 509
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →